Mixed Phenotype Acute Leukemia — Trials

Mixed Phenotype Acute Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

96 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 29
Ph III recruiting: 2
Growth YoY: —
Industry share: 17%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: 41.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–20 of 20 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04065399	A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation(AUGMENT-101)	recruiting	Phase 1 / Phase 2	447	Syndax PharmaceuticalsINDUSTRY	11	Sep 16, 2026	clinicaltrials
NCT03683433	Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	recruiting	Phase 2	50	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026